MENLO PARK, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. PACB today announced financial results for its second quarter ended June 30, 2018.
Total revenue for the second quarter of 2018 was $21.6 million, compared to $20.1 million for the second quarter of 2017.
Gross profit for the second quarter of 2018 was $8.9 million, resulting in a gross margin of 41.1%. Gross profit for the second quarter of 2017 was $8.0 million, resulting in a gross margin of 39.9%.
Operating expenses for the second quarter of 2018 totaled $30.6 million, compared to $32.4 million for the second quarter of 2017. Operating expenses for the second quarter of 2018 and 2017 included non-cash stock-based compensation of $4.6 million and $4.4 million, respectively.
Net loss for the second quarter of 2018 was $22.5 million, compared to $25.5 million for the second quarter of 2017.
Cash, cash equivalents and investments, excluding restricted cash, at June 30, 2018 totaled $63.5 million, compared to $62.9 million at December 31, 2017.
Quarterly Conference Call Information
Management will host a quarterly conference call to discuss its second quarter ended June 30, 2018 results today at 4:30 p.m. Eastern Time. Investors may listen to the call by dialing 1.888.366.7247, or if outside the U.S., by dialing +1.707.287.9330, using Conference ID # 2075988. The call will be webcast live and will be available for replay at Pacific Biosciences' website at http://investor.pacificbiosciences.com/.
About Pacific Biosciences
Pacific Biosciences of California, Inc. PACB offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) Technology, Pacific Biosciences' products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences' technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the timeline for Pacific Biosciences' potential development of products, future uses, quality or performance of, or benefits of using, products or technologies and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences' control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences' most recent filings with the Securities and Exchange Commission, including Pacific Biosciences' most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption "Risk Factors." Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.
Contact:
Trevin Rard
650.521.8450
ir@pacificbiosciences.com
| Pacific Biosciences of California, Inc. | |||||||||||||||||||||||||||||
| Unaudited Condensed Consolidated Statement of Operations | |||||||||||||||||||||||||||||
| (amounts in thousands, except per share amounts) | |||||||||||||||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||||||||
| 2018 | 2017 | 2018 | 2017 | ||||||||||||||||||||||||||
| Revenue: | |||||||||||||||||||||||||||||
| Product revenue | $ | 18,485 | $ | 16,548 | $ | 34,767 | $ | 37,842 | |||||||||||||||||||||
| Service and other revenue | 3,093 | 3,525 | 6,173 | 7,146 | |||||||||||||||||||||||||
| Total revenue | 21,578 | 20,073 | 40,940 | 44,988 | |||||||||||||||||||||||||
| Cost of Revenue: | |||||||||||||||||||||||||||||
| Cost of product revenue | 9,858 | 8,155 | 18,877 | 19,517 | |||||||||||||||||||||||||
| Cost of service and other revenue | 2,858 | 3,917 | 5,905 | 8,533 | |||||||||||||||||||||||||
| Total cost of revenue | 12,716 | 12,072 | 24,782 | 28,050 | |||||||||||||||||||||||||
| Gross profit | 8,862 | 8,001 | 16,158 | 16,938 | |||||||||||||||||||||||||
| Operating Expense: | |||||||||||||||||||||||||||||
| Research and development | 15,664 | 16,883 | 31,975 | 33,854 | |||||||||||||||||||||||||
| Sales, general and administrative | 14,943 | 15,505 | 29,877 | 30,770 | |||||||||||||||||||||||||
| Total operating expense | 30,607 | 32,388 | 61,852 | 64,624 | |||||||||||||||||||||||||
| Operating loss | (21,745 | ) | (24,387 | ) | (45,694 | ) | (47,686 | ) | |||||||||||||||||||||
| Interest expense | (598 | ) | (826 | ) | (1,179 | ) | (1,664 | ) | |||||||||||||||||||||
| Other income (expense), net | (197 | ) | (326 | ) | 154 | (56 | ) | ||||||||||||||||||||||
| Net loss | $ | (22,540 | ) | $ | (25,539 | ) | $ | (46,719 | ) | $ | (49,406 | ) | |||||||||||||||||
| Basic and diluted net loss per share | $ | (0.17 | ) | $ | (0.26 | ) | $ | (0.37 | ) | $ | (0.52 | ) | |||||||||||||||||
| Shares used in computing basic and diluted net loss per share | 131,882 | 97,360 | 127,847 | 95,177 | |||||||||||||||||||||||||
| Pacific Biosciences of California, Inc. | |||||
| Unaudited Condensed Consolidated Balance Sheets | |||||
| (amounts in thousands) | |||||
| June 30, | December 31, | ||||
| 2018 | 2017 | ||||
| Assets | |||||
| Cash and investments | $ | 63,491 | $ | 62,872 | |
| Accounts receivable | 7,446 | 13,433 | |||
| Inventory | 23,440 | 23,065 | |||
| Prepaid and other current assets | 2,035 | 2,249 | |||
| Property and equipment | 36,103 | 37,920 | |||
| Long-term restricted cash | 4,500 | 4,500 | |||
| Other long-term Assets | 43 | 45 | |||
| Total Assets | $ | 137,058 | $ | 144,084 | |
| Liabilities and Stockholders' Equity | |||||
| Accounts payable | $ | 4,169 | $ | 9,093 | |
| Accrued expenses | 10,935 | 12,618 | |||
| Deferred service revenue | 7,469 | 7,394 | |||
| Deferred rent | 14,106 | 14,453 | |||
| Other liabilities | 744 | 605 | |||
| Financing derivative | 40 | 183 | |||
| Notes payable | 14,121 | 13,635 | |||
| Stockholders' equity | 85,474 | 86,103 | |||
| Total Liabilities and Stockholders' Equity | $ | 137,058 | $ | 144,084 | |
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
